Merger Arbs See Wide-Open Deal Window With Biotech Top of List

Merger arbitrage investors — fresh off a boom year for dealmaking — expect no let-up in the trend, with biotechnology firms seen as leading the pack among potential takeover candidates...

By Joel Leon, Neil Campling · Bloomberg Markets

Merger arbitrage investors — fresh off a boom year for dealmaking — expect no let-up in the trend, with biotechnology firms seen as leading the pack among potential takeover candidates in the first quarter.